Recent Updates
Recently added Catalysts

Upcoming Catalyst

Drug Pipeline Intelligence

Clinical Trial Results

Inside Trades

Options Data

News Section

Hedge Funds

Ownership Trends

Competitive Position

Arbutus Biopharma Corporation

35 indications, side-by-side phase, drug & LoA

$4.26

-0.03 (-0.7%)

D 35Pipeline Score Overvalued Pharma · Commercial
Market Cap
841.51 M
EPS
0.83
P/E Ratio
5.18 $
Value Trade
7.43 M
SEC Financials
Q1 2026

  • Dilution Risk

    5%

  • Revenue

    179.13 M

  • R&D Expenses

    4.12 M

  • Operating CF

    -8.11 M

  • Total Assets

    277.16 M

  • Total Liabilities

    16.99 M

  • Equity

    260.18 M

  • D/E Ratio

    12,345

1.16 %
Week
-2.47 %
1 Month
3.57 %
3 Month
4.57 %
6 Month
55.36 %
5 Year
-39.73 %
All Time
Cash Data
Healthy

  • Cash Position

    95.23 M

  • Monthly Burn

    2.70 M

  • Runway

    34.3 mo

  • Burn Trend

    Decelerating

  • SEC Filing

    May 13, 2026
Overview
Volume
1.01 M
52 Week Range
3.04 - 5.10
% held by Insiders
20.46 %
% held by Institutions
70.92 %
Enterprise Value
750.19 M
Total Shares
196.82 M
Short %
10.85 %
Float Shares
156.47 M
Company Description
HQ: 701 VETERANS CIRCLE, WARMINSTE...
Founded:2005
Employees:19
http://www.arbutusbio.com

locked

Upcoming Catalyst
Catalyst Drug/Treatment Stage Probability of Approval Description Drug Type Therapeutic Area Source
PDUFA 2026
Example Drug Treatment for example condition requiring FDA review
Phase 3
-%
Small Molecule
Oncology
Example Drug Treatment for example condition requiring FDA review
Phase 3
-%
Small Molecule
Oncology
Example Drug Treatment for example condition requiring FDA review
Phase 3
-%
Small Molecule
Oncology
Unlock Upcoming Catalyst data
Drug Pipeline Intelligence
D35
Pipeline Score
$273M
Pipeline Value
Overvalued
Valuation Signal
5
Drugs Scored
0.3x
rNPV / MCap
Top 48%
Micro Cap
(rank 472 of 905)
Percentile Rank
Arbutus Biopharma Corporation faces pipeline headwinds (35/100), with $683M risk-adjusted pipeline value, led by AB-729 in Chronic Hepatitis b (Phase 2).
Showing 1 of 1 assets
DrugIndicationPhaseNCT IDPTRSrNPVStatusEnrollmentVelocityDesignCompletionML SignalLast Change
AB-729
Small molecule		Chronic Hepatitis bPhase 2NCT0498048221% $193M COMPLETED 43 - -May 21, 2025 -MEDIUM
May 30, 2026
Unlock Drug Pipeline Intelligence
Clinical Trial Results
Drug Name Indications Phase Date Trial Results Summary Title Source
Imdusiran
Chronic Hepatitis B Virus (cHBV)
Phase 2a
2025-06-25
Imdusiran
Chronic Hepatitis B Virus (cHBV)
Phase 2a
2025-06-25
Imdusiran
Chronic Hepatitis B Virus (cHBV)
Phase 2a
2025-06-25
Unlock Clinical Trial Results data
Inside Trades
TREND
CORPORATE INSIDERS BOUGHT SHARES WORTH 1.8M IN THE LAST 3 MONTHS
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Unlock Inside Trades data
Show Data
Hedge Funds
TREND
HEDGE FUNDS INCREASED HOLDINGS BY 200.0K SHARES IN THE LAST QUARTER
Shares Held
2040.00B1530.00B1020.00B510.00B0
Q3
2024
Q4
2024
Q1
2025
Q2
2025
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Fund Count
60%
Share Volume
25%
Conviction
15%
Hedge Funds invested in ABUS
HedgeFund Name
( 3 )
% of Portfolio Current MV
-
Shares Owned
-
Activity
Avg Price $0

Example Capital Management

2.5 %
15.00 M
250.00 K

Example Capital Management

2.5 %
15.00 M
250.00 K

Example Capital Management

2.5 %
15.00 M
250.00 K
Unlock Hedge Funds table data
Biotech Analyst Ratings
Symbol
Firm
Rating
Action
Price Target
Upside
date
ABUS
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
ABUS
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
ABUS
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
Unlock Biotech Analyst Ratings data
ABUS Stock Forecast & Analyst Consensus
BUY
Analyst Ratings
Buy65.0%
Hold25.0%
Sell10.0%
Price Target Trend
Average$24.00
Low$18.00
High$32.00
Unlock Price Target Trend
ABUS Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
ExpirationVolumeOpen InterestImplied Volatility CallsImplied Volatility Puts
CallsPutsPut-Call RatioCallsPutsPut-Call RatioIVOiWaIvVWaIvIVOiWaIvVWaIv
2026-12-18 0.00 0 - - - - - -
2026-12-18 0.00 0 - - - - - -
2026-12-18 0.00 0 - - - - - -
Unlock Option Chain Statistics data
Option Chain
CallsStrikePuts
Last PriceVolumeOpen InterestLast PriceVolumeOpen Interest
No data available
Unlock Option Chain data
Unlock Options Chart data
Open interest
0 600K 1.2M 1.8M Avg OI 1.00 M Open Interest
0 1 2 3 1.1 Put-Call Ratio
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
0 450K 900K 1.4M Avg OV 750.00 K Option Volume
0 1 2 3 0.95 Put-Call Ratio
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Latest Arbutus Biopharma Corporation (ABUS) News & Alerts
-
Sunday, June 14, 2026
(%)
+ More

Demo Biotech Announces Positive Phase 3 Results

Competitive Position
How ABUS ranks across every disease it competes in
No competitive intelligence available for ABUS.